This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects

1. Browse more Reports on cancer therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-
therapeutics .
Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015
By
RnRMarketResearch.com
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Publisher Name : Global Markets Direct
Date: 30-Jun-2015
No. of pages: 431
Single User License: US $2000

2. This report provides comprehensive information on the therapeutic development
for Refractory Acute Myeloid Leukemia, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type, along with latest
updates, and featured news and press releases. It also reviews key players
involved in the therapeutic development for Refractory Acute Myeloid Leukemia
and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective
counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class
products.
Refractory Acute Myeloid Leukemia - Pipeline
Review, H1 2015
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441

3. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Refractory Acute Myeloid Leukemia - Pipeline
Review, H1 2015
Companies Discussed/Mentioned in this Research :
4SC AG, AbbVie Inc., Actinium Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Amgen
Inc., Arog Pharmaceuticals, Inc., Array BioPharma Inc., Astellas Pharma Inc., Astex
Pharmaceuticals, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Boehringer Ingelheim
GmbH, Bristol-Myers Squibb Company, Calithera Biosciences, Inc., Celgene Corporation,
Conkwest, Inc., Cornerstone Pharmaceuticals, Inc., CTI BioPharma Corp. and some more..
Drugs Profile Discussed in this Research :
4SC-202, AG-120, alvocidib hydrochloride, AMG-232, AT-9283, BI-836858, binimetinib,
bortezomib, brentuximab vedotin, burixafor, cabozantinib s-malate, cafusertib
hydrochloride, CB-839, CC-90007, Cell Therapy to Target CD123 for Relapsed and
Refractory Acute Myeloid Leukemia, Cell Therapy to Target CD33 for Acute Myeloid
Leukemia, Cell Therapy to Target Tumor Associated Antigen for Hematopoietic
Malignancies, CPI-613 and more…

4. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Scope For Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015
• The report provides a snapshot of the global therapeutic landscape of Refractory
Acute Myeloid Leukemia
• The report reviews key pipeline products under drug profile section which
includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
• The report reviews key players involved in the therapeutics development for
Refractory Acute Myeloid Leukemia and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Refractory Acute Myeloid Leukemia products under development
by companies and universities/research institutes based on information derived
from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages.
Refractory Acute Myeloid Leukemia - Pipeline
Review, H1 2015

5. © http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Reasons to Buy:
• Provides strategically significant competitor information, analysis, and
insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading
companies
• Identify and understand important and diverse types of therapeutics
under development for Refractory Acute Myeloid Leukemia
• Plan mergers and acquisitions effectively by identifying key players of the
most promising pipeline
• Devise corrective measures for pipeline projects by understanding
Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication
therapeutics
Refractory Acute Myeloid Leukemia - Pipeline
Review, H1 2015

6. For more details contact Mr. Ritesh Tiwari : sales@rnrmarketresearch.com / +18883915441
RnRMarkertResearch
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports by
leading market research publishers across the globe.
© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com
+1 888 391 5441
Refractory Acute Myeloid Leukemia - Pipeline
Review, H1 2015